Molecular classification of cholangiocarcinoma.
Journal
Current opinion in gastroenterology
ISSN: 1531-7056
Titre abrégé: Curr Opin Gastroenterol
Pays: United States
ID NLM: 8506887
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
3
1
2020
medline:
21
10
2020
entrez:
3
1
2020
Statut:
ppublish
Résumé
Cholangiocarcinoma (CCA) are heterogeneous tumors that arise from the malignant transformation of cholangiocytes along the biliary tree. CCA heterogeneity occurs at multiple levels and results in resistance to therapy and poor prognosis. Here, we review the molecular classification of CCA by focusing on the latest progresses based on genetic, epigenetic, transcriptomic and proteomic profiles. In addition, we introduce the emerging field of radiogenomics. Genome-wide integrative omics approaches have been widely reported by using large cohorts of CCA patients. Morphomolecular correlations have been established, including enrichment of FGFR2 gene fusions and IDH1/2 mutations in iCCA. A specific IDH mutant iCCA subtype displays high mitochondrial and low chromatin modifier expression linked to ARID1A promoter hypermethylation. Examples of translation of these classifications for the management of CCA have also been reported, with prediction of drug efficacy based on genetic alterations. Although there is currently no international consensus on CCA morphomolecular classification, the recent initiatives developed under the umbrella of The European Network for the Study of Cholangiocarcinoma (ENSCCA) should favor new collaborative research. Identifying distinct molecular subgroups and developing appropriate targeted therapies will improve the clinical outcome of patients with CCA.
Identifiants
pubmed: 31895230
doi: 10.1097/MOG.0000000000000611
pii: 00001574-202003000-00003
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-62Références
Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 2019; 71:104–114.
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60:1268–1289.
Bragazzi MC, Ridola L, Safarikia S, et al. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. Ann Gastroenterol 2018; 31:42–55.
Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the u.S.: Intrahepatic disease on the rise. Oncologist 2016; 21:594–599.
Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int 2019; 39: (Suppl 1): 7–18.
Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017; 6:22–34.
Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13:261–280.
Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2012; 28:266–272.
Putra J, de Abreu FB, Peterson JD, et al. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol 2015; 99:240–244.
Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015; 47:1003–1010.
Nepal C, O’Rourke CJ, Oliveira D, et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology 2018; 68:949–963.
Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun 2014; 5:5696.
Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012; 142:1021.e15–1031.e15.
Ang C. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma. J Gastroenterol Hepatol 2015; 30:1116–1122.
Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov 2017; 7:943–962.
O’Rourke CJ, Munoz-Garrido P, Aguayo EL, Andersen JB. Epigenome dysregulation in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2018; 1864 (4 Pt B):1423–1434.
Goeppert B, Konermann C, Schmidt CR, et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology 2014; 59:544–554.
Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 2017; 7:1116–1135.
Kim Y, Lee K, Jeong S, et al. Dlec1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype. Virchows Arch 2019; 475:49–58.
Merino-Azpitarte M, Lozano E, Perugorria MJ, et al. Sox17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. J Hepatol 2017; 67:72–83.
Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013; 144:829–840.
Chaisaingmongkol J, Budhu A, Dang H, et al. TIGER-LC Consortium. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 2017; 32:57.e53–70.e53.
Farshidfar F, Zheng S, Gingras MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep 2017; 19:2878–2880.
Salati M, Braconi C. Noncoding RNA in cholangiocarcinoma. Semin Liver Dis 2019; 39:13–25.
Li J, Huang L, Li Z, et al. Functions and roles of long noncoding RNA in cholangiocarcinoma. J Cell Physiol 2019; 234:17113–17126.
Angenard G, Merdrignac A, Louis C, et al. Expression of long noncoding RNA anril predicts a poor prognosis in intrahepatic cholangiocarcinoma. Dig Liver Dis 2019; 51:1337–1343.
Liang Z, Zhu B, Meng D, et al. Down-regulation of lncRNA-NEF indicates poor prognosis in intrahepatic cholangiocarcinoma. Biosci Rep 2019; 39: pii: BSR20181573.
pii: bsr20181573
Gentilini A, Pastore M, Marra F, Raggi C. The role of stroma in cholangiocarcinoma: the intriguing interplay between fibroblastic component, immune cell subsets and tumor epithelium. Int J Mol Sci 2018; 19: pii: E2885.
pii: e2885
Hogdall D, Lewinska M, Andersen JB. Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma. Trends Cancer 2018; 4:239–255.
Sulpice L, Rayar M, Desille M, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013; 58:1992–2000.
Kriegsmann M, Roessler S, Kriegsmann K, et al. Programmed cell death ligand 1 (pd-l1, cd274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies. BMC Cancer 2019; 19:72.
Fontugne J, Augustin J, Pujals A, et al. Pd-l1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 2017; 8:24644–24651.
Le Faouder J, Gigante E, Leger T, et al. Proteomic landscape of cholangiocarcinomas reveals three different subgroups according to their localization and the aspect of nontumor liver. Proteomics Clin Appl 2019; 13:e1800128.
Saini A, Breen I, Pershad Y, et al. Radiogenomics and radiomics in liver cancers. Diagnostics (Basel) 2018; 9: pii: E4.
pii: e4
Sadot E, Simpson AL, Do RK, et al. Cholangiocarcinoma: correlation between molecular profiling and imaging phenotypes. PLoS One 2015; 10:e0132953.